Published On: Wed, Oct 19th, 2016

Incyte Corporation (NASDAQ:INCY) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of Incyte Corporation (NASDAQ:INCY).

Most recent broker ratings

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at Cowen.

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 98 price target on the stock.

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 116 price target on the stock.

10/07/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 121 price target on the stock.

09/29/2016 – Incyte Corporation was upgraded to “outperform” by analysts at Raymond James. They now have a USD 115 price target on the stock.

09/26/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at Argus. They now have a USD 98 price target on the stock.

08/16/2016 – Incyte Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 102 price target on the stock.

08/10/2016 – Incyte Corporation had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 100 price target on the stock.

08/05/2016 – SunTrust began new coverage on Incyte Corporation giving the company a “buy” rating. They now have a USD 105 price target on the stock.

06/29/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at Goldman Sachs.

06/14/2016 – Incyte Corporation had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 100 price target on the stock.

04/18/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 88 price target on the stock.

03/23/2016 – Morgan Stanley began new coverage on Incyte Corporation giving the company a “overweight” rating. They now have a USD 85 price target on the stock.

02/12/2016 – Incyte Corporation had its “buy” rating reiterated by analysts at UBS. They now have a USD 88 price target on the stock.

02/12/2016 – Incyte Corporation had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 108 price target on the stock.

The share price of Incyte Corporation (NASDAQ:INCY) was up +2.40% during the last day of trading, with a day high of 89.79. 1067365 shares were traded during the last session.

The stock’s 50 day moving average is 87.09 and its 200 day moving average is 81.92. The stock’s market capitalization is 16.69B. Incyte Corporation has a 52-week low of 55.00 and a 52-week high of 124.98.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.